STOPPING TB IN MY LIFETIME
MARCH 23, 2012
8:30 AM - 4:00 PM
CNE/CME CERTIFIED ACTIVITY

Course Location
New York City Department of Health & Mental Hygiene
Gotham Center, Auditorium 03-32
42-09 28 Street
Queens, NY 11101-4132

Jointly Sponsored By
The New York City Department of Health & Mental Hygiene, New Jersey Medical School
Global Tuberculosis Institute, and UMDNJ-Center for Continuing and Outreach Education

The New Jersey Medical School Global Tuberculosis Institute is the tuberculosis Regional Training and Medical Consultation
Center for the Northeastern United States

This activity is supported by an educational grant from the Centers for Disease Control and Prevention,
Division of Tuberculosis Elimination

WHY COURSE IS NEEDED

The management of TB requires a multidisciplinary approach which relies on knowledge of the most current
information of TB rates, populations at risk and interventions that are successful. This conference will provide
a forum for learning this information as well as for discussion among colleagues.

COURSE DESCRIPTION & OVERALL GOAL

In commemoration of World TB Day, this conference will address TB prevention and control efforts in New
York City to highlight progress in the fight against TB. Topics will include a review of the local epidemiology,
taking steps to address TB among the foreign born, new treatment options for latent TB infection, laboratory
testing for TB, working with prison populations, and managing TB and co-morbidities. Case studies and
question and answer sessions will be included to enhance discussions as well as to share experiences.

COURSE REQUIREMENTS

In order to meet the learning objectives and receive continuing education credits, participants are required to
attend the entire conference and complete an online evaluation form. A post-course follow-up evaluation will
be sent within 2 months of the course.

WHO SHOULD ATTEND

This conference is open to providers (pulmonary, infectious disease, community health, infection control) and
health care workers who manage patients at risk for or diagnosed with TB.
OBJECTIVES

Upon completion of this conference, participants will be able to:

- Apply current recommendations for the treatment of latent TB infection to improve treatment outcomes
- Describe the available laboratory testing for the diagnosis of TB and monitoring patient response to therapy
- Describe the rationale, methods, and implementation of needs assessment conducted as part of the New York City Foreign-Born Initiative
- Discuss the principles of TB screening, diagnosis and treatment in correctional facilities
- Explain the relationship between TB and other co-morbid conditions to ensure proper diagnosis and treatment

FACULTY LIST

Brown University School of Medicine
E. Jane Carter, MD – Associate Professor of Medicine

Centers for Disease Control & Prevention – Division of TB Elimination
Sundari Mase, MD, MPH – Team Lead for Medical Affairs, Field Services & Evaluation Branch

Columbia University
Neil Schluger, MD – Chief, Division of Pulmonary, Allergy & Critical Care Medicine and Professor of Medicine, Epidemiology & Environmental Sciences

NJMS Global Tuberculosis Institute
Alfred Lardizalab – Associate Director

New York City Department of Health & Mental Hygiene
Felicia Dworkin, MD – Deputy Director of Medical Affairs
Diana Nilsen, MD – Director of Medical Affairs
Farah Parvez, MD, MPH – Medical Director, Office of Correctional Public Health
Jennifer Rakeman, PhD – Associate Director, Microbiology Section, Public Health Laboratory
Alexandra Santana Camacho, MPH, LMSW – Public Health Prevention Service Fellow, CDC

New York State Department of Health
Margaret Oxtoby, MD – Director, Bureau of Tuberculosis Control

PLANNING COMMITTEE

New Jersey Medical School Global TB Institute
Anita Khilall, MPH – Senior Training & Consultation Specialist
Anna Sevilla, MPH – Research Coordinator

New York City Department of Health & Mental Hygiene
Martha Alexander, MHS – Director of Education, Training & Outreach
Elvy Baroso, MSc, RN – Professional Development Coordinator
Diana Nilsen, MD – Director of Medical Affairs
Angel Roca – Deputy Director

AGENDA

8:30 am  Registration
9:00 am  Opening Remarks / Epidemiology of TB in NYC
Diana Nilsen, MD
9:15 am New Modalities in the Treatment of Latent TB Infection
Neil Schluger, MD
10:15 am Laboratory Testing for Diagnosis and Treatment of TB
   Jennifer Rakeman, PhD
11:05 am Break
11:15 am Foreign-Born Initiative: Engaging Patients, Providers and Communities through Needs Assessments
   Alexandra Santana Camacho, MPH, LMSW
12:00 pm Lunch
1:00 pm Corrections & TB: Working with Prison Populations
   Farah Parvez, MD, MPH & Margaret Oxtoby, MD
1:45 pm TB and Co-Morbid Conditions
   E. Jane Carter, MD
2:35 pm Break
2:45 pm Ask a TB Expert
   E. Jane Carter, MD, Alfred Lardizabal, MD, Diana Nilsen, MD, Neil Schluger, MD,
   Sundari Mase, MD, MPH and Margaret Oxtoby, MD
3:15 pm Case Studies
   Alfred Lardizabal, MD & Felicia Dworkin, MD
3:45 pm Closing Remarks / Evaluation

CONTINUING EDUCATION INFORMATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ - Center for Continuing and Outreach Education and the New York City Department of Health and Mental Hygiene Bureau of TB Control. UMDNJ - Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.

UMDNJ - Center for Continuing and Outreach Education designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

UMDNJ-Center for Continuing and Outreach Education is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center's COA. Provider Number P173-11/09-12. Provider Approval is valid through November 30, 2012.

This activity is awarded 5.67 contact hours (60 minute CH).

Nurses should only claim those contact hours actually spent participating in the activity.

Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.

Approved provider status refers only to continuing education activities and does not imply ANCC COA or NJSNA endorsement of any commercial products.

PEER REVIEW STATEMENT

This activity has been peer reviewed for relevance, accuracy of content and balance of presentation by Anna Sevilla, MPH, Elvy Baroso, MSc, RN, and Anita Khilall, MPH.

DISCLOSURE DISCLAIMER

In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months;
and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

The following faculty and planning committee members have stated that they have no relevant financial relationships to disclose:

Martha Alexander, MHS
Elvy Baroso, MSc, RN
E. Jane Carter, MD
Felicia Dworkin, MD
Anita Khilall, MPH
Alfred Lardizabal, MD
Sundari Mase, MD, MPH
Diana Nilsen, MD
Margaret Oxtoby, MD
Farah Parvez, MD, MPH
Jennifer Rakeman, PhD
Angel Roca
Alexandra Santana Camacho, MPH, LMSW
Neil Schluger, MD
Anna Sevilla, MPH

Off-Label/Investigational Use Disclosure
This activity will include discussion of off-label use of short course therapy (12 doses of Isoniazid and Rifapentine using directly observed therapy) for the treatment of latent TB infection.

This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation.

CONTENT DISCLAIMER

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals, UMDNJ, NJMS Global Tuberculosis Institute, or NYC Health Department. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. UMDNJ, NJMS Global Tuberculosis Institute, and NYC Department of Health reserve the right to modify the activity content and faculty if necessary.

COPYRIGHT

Copyright ©2012 UMDNJ-Center for Continuing and Outreach Education and NJMS Global Tuberculosis Institute. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education.